A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stressXie‐an Yu, Jiangwei Tian, Mi Lu et al.|Theranostics|2019Cited by 51
The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysisYing Zhang, Yufei Feng, Xingxian Luo et al.|Mycoses|2021Cited by 38
Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysisYing Zhang, Yufei Feng, Xu Hao et al.|Pharmacogenetics and Genomics|2022Cited by 9
Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese populationYuanyuan Li, Lin Huang, Ying Zhang et al.|Journal of Chemotherapy|2023Cited by 8
Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimizationXu Hao, Lin Huang, Yuanyuan Li et al.|British Journal of Clinical Pharmacology|2023Cited by 8